REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai > Phosphorus Containing Phosphorus ContainingPhosphorus Containing patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.03/01/07 - 20070049519 - Glycopeptide phosphonate derivatives Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents. ... 03/01/07 - 20070049518 - Novel method of treatment of inflammatory skin conditions There is provided, inter alia, a method for the treatment or prevention of an inflammatory skin condition which is characterised by colonisation with Staphylococcus aureus, comprising the topical administration of an aureolysin inhibitor. ... 02/22/07 - 20070042940 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are ... 02/22/07 - 20070042939 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are ... 02/22/07 - 20070042938 - Use of dpiv and apn inhibitors for the treatment of dermatalogical diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts The invention relates to a process for the inhibition of the DNA synthesis (essential for the proliferation) of human fibroblasts by a single or joint effect of inhibitors of alanyl aminopeptidase (APN) and dipeptidyl peptidase IV (DPIV) expressed by those cells. The DNA synthesis (proliferation) of human fibroblasts is inhibited, ... 02/01/07 - 20070027067 - Transition-state inhibitors of pin1, alpha-ketoamide-containing peptidomimetics, and synthesis thereof Novel α-ketoamide-containing peptidomimetics are provided, such as peptidomimetics containing an α-ketoamide Ser-Pro dipeptide analogue. The α-ketoamide is preferably incorporated into another molecule as a Pin1 inhibitor (such as a pentapeptide analogue Ac-Phe-Tyr-pSer-Pro-Arg-NH2). ... 02/01/07 - 20070027066 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are ... 02/01/07 - 20070027065 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are ... 01/25/07 - 20070021327 - Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the ... 01/11/07 - 20070010429 - Phospholipid formulations and uses thereof in lung disease detection and treatment Disclosed are methods and compositions that are useful in the detection and therapy of diseases (e.g., emphysema) and damage that afflict the lungs. In some aspects, the compositions comprise a formulation enriched for a species of phosphatidylcholine, such as palmitoylmyristoyl phosphatidylcholine (16:0/14:0PC). The compositions may further be described as lung ... 01/11/07 - 20070010428 - Inhibitors of signal transduction and activator of transcription 3 Stat3 inhibitor compounds are disclosed, wherein the compounds are structural analogs of Ac-pTyr-Leu-Pro-Gln-Thr-NH2 and bind to the SH2 domain of Stat3 under physiological conditions to inhibit a cellular signaling activity of Stat3. ... 01/04/07 - 20070004618 - Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin Disclosed herein are hemojuvelin-specific siRNAs that vary hemojuvelin mRNA concentration. Also disclosed herein, GPI-hemojuvelin positively regulated hepcidin mRNA expression, independently of the IL-6 pathway, whereas soluble hemojuvelin (s-hemojuvelin) suppressed hepcidin mRNA expression in primary human hepatocytes in a log-linear dosedependent manner. Disclosed are compositions and methods for modulating diseases of ... 12/28/06 - 20060293220 - Calcium phosphate nanoclusters and their applications Artificial particles known as calcium phosphate nanoclusters are disclosed. The particles contain high concentrations of calcium, particularly for use in nutritional products, neutraceuticals, and pharmacological preparations. ... 11/16/06 - 20060258566 - Compounds for targeting endothelial cells, compositions containing the same and methods for their use The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy. ... 11/16/06 - 20060258565 - Methods of inhibiting viral infection The present invention is directed to methods of preventing and/or treating infectious disease. In a particular aspect, the invention is directed to preventing and/or treating viral infections. ... 11/16/06 - 20060258564 - Method for synthesizing conformationally constrained peptides, peptidomimetics and the use thereof as synthetic vaccines The present invention relates to methods for synthesizing conformationally constrained peptides and cyclic peptidomimetics obtainable by these methods which are conformationally constrained due an internal cross-link. This cross-link is formed between the side chain of an amino acid residue or analog and a (2S, 4S)4-functionalized proline residue. The invention further ... 10/26/06 - 20060241021 - Methods of treating cognitive dysfunction by modulating brain energy metabolism Methods for treating cognitive dysfunction by modulating brain energy metabolism are discussed. ... 10/26/06 - 20060241020 - Protein tyrosine phosphatase inhibitors The invention relates to phosphopeptides inhibiting protein tyrosine phosphatases, and their uses. ... 10/19/06 - 20060234916 - Cardioprotective agent A problem of the present invention is to provide an agent which allows effective protection of cardiac damage in a case where a variety of symptoms such as arrhythmia, cardiac desmoplasia and heart-failure are likely to accompany with hypertension, hypercardia, myocardial infarction, arteriosclerosis, diabetic and non-diabetic renal diseases, and re-stenosis ... 10/12/06 - 20060229235 - Synthetic mimics of mammalian cell surface receptors: method and compositions The present invention relates to new synthetic receptors. More particularly, the present invention relates to the use of the synthetic receptors for delivering a protein, peptide, drug, prodrug, lipid, nucleic acid, carbohydrate or small molecule into a target cell via receptor-mediated endocytosis. According to the invention, novel synthetic mimics of ... 10/05/06 - 20060223743 - Metabolites of cyclosporin analogs Isolated metabolites of the cyclosporine analog ISA247 are disclosed, including in vitro methods for their preparation. The metabolites comprise a chemical modification of ISA247, wherein the modification is at least one reaction selected from the group consisting of hydroxylation, N-demethylation, diol formation, epoxide formation, and intramolecular cyclization phosphorylation, sulfation, glucuronide ... 10/05/06 - 20060223742 - Clinical method for the immunomodulatory and vaccine adjuvant use of poly-iclc and other dsrnas An improved understanding and method for the clinical adjuvant and immunomodulatory use of dsRNAs and ply-ICLC in particular, alone or in conjunction with other drugs and various vaccines designed to prevent or treat various microbial, viral, neoplastic, autoimmune diseases, and or degenerative diseases. ... 09/28/06 - 20060217292 - Vitronectin receptor antagonist compounds and their use in the preparation of diopharmaceuticals The present invention is directed to a compound comprising a thiol derivatized targeting moiety. The targeting moiety binds to a receptor which his upregulated during angiogenesis. ... 09/21/06 - 20060211602 - Use of alanyl aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors The present invention relates to the use of one inhibitor or of several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity for the induction of the production of TGF-β1 and of the expression of TGF-β1 in and/or on Treg cells and relates to the use for ... 09/14/06 - 20060205635 - Antigene oligomers inhibit transcription Transcription of a gene in a mammalian cell is methylase-independently inhibited by contacting the cell with a nucleic acid oligomer of 12-28 bases complementary for a partially single-stranded target genomic sequence of the gene. ... 08/31/06 - 20060194714 - Novel depsipeptides and process for preparing same The present invention relates to novel depsipeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel depsipeptide compounds and intermediates used in producing these compounds. ... 08/10/06 - 20060178297 - Systems and methods for silencing expression of a gene in a cell and uses thereof The present invention provides RNA-based systems that are capable of silencing expression of a gene in a cell. Also provided are pharmaceutical compositions, cells, and kits that include the systems; cultures of primary cells that have been contacted with the systems; use of the systems in methods of studying protein ... 07/27/06 - 20060166866 - Cell adhesion inhibitors The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and ... 07/27/06 - 20060166865 - Methods and compositions for treating flaviviruses and pestiviruses A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided. ... 07/20/06 - 20060160725 - Lipid metabolism improving agent The present invention relates to a protein/phospholipid or protein hydrolyzate/phospholipid complex containing 10 wt % or more of bound phospholipid, a lipid metabolism improving agent comprising the complex, and a functional food comprising the complex. The present invention provides a lipid metabolism improving agent and a functional food, containing the ... 07/13/06 - 20060154854 - Molecules for targeting and releasing therapeutic compounds, and the use thereof The invention relates to chimera molecules for targeting and releasing therapeutic compounds in mammals, especially humans. The inventive molecules comprise essentially three functional segments or domains: a targeting segment that can preferentially bind to the surface of the targeted cells, a therapeutic segment comprising the biologically active compound, and a ... 07/06/06 - 20060148678 - Novel acyl-dipeptide-like compounds, a method for preparing the same and pharmaceutical compositions containing such products wherein substituents A, B, X, Y, R1, R2, and subscripts n, m, p and q have the same meanings as those given in the claims. The invention is equally directed to pharmaceutical compositions containing as an active ingredient at least one compound of general formula I either in acid or ... 06/29/06 - 20060142184 - Protein based oral lubricant The present invention relates to formulations containing phosphoprotein, designed for use as oral lubricant or as artificial saliva, methods of using the formulations and processes for the preparation of the formulations. ... 06/22/06 - 20060135409 - Process for and intermediates in the preparation of canfosfamide and its salts A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity. ... 06/22/06 - 20060135408 - Glycogen synthase kinase-3 inhibitors Novel conjugates that are capable of inhibiting GSK-3 activity, a process of producing same, pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions are disclosed. Methods of treating affective disorders using GSK-3 inhibitors are further disclosed. ... 06/08/06 - 20060122101 - Drug for preventing, regulating or treating adhesion A problem of the present invention is to provide a medicament which allows effective prevention, inhibition, or treatment of adhesion formation, comprising using before or after a variety of surgical treatments including orthopedic or plastic surgery, for example, in cardiac, thoracic, gynecological, ophthalmic, abdominal sites or in the case where ... 05/25/06 - 20060111277 - Echinocandin/carbohydrate complexes A complex of an echinocandin compound with a carbohydrate is described having improved thermal stability and water solubility. A process for making the echinocandin/carbohydrate complex is also described as well as the use of the complex in pharmaceutical formulations and treatments of fungal infections. ... 05/25/06 - 20060111276 - Cidofovir peptide conjugates as prodrugs Cidofovir-based compounds having an amino acid, dipeptide or tripeptide attached to a cidofovir or cyclic cidofovir framework. The compounds show enhanced oral bioavailability and increased binding to the PepT1 transporter. The present invention also provides compositions and methods for treating virus infections, and a method of preparing cidofovir. ... 03/23/06 - 20060063706 - Glycopetide phosphonate derivatives Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents. ... 03/02/06 - 20060046957 - Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain. ... 02/16/06 - 20060035815 - Pharmaceutical compositions for delivery of ribonucleic acid to a cell What is disclosed is a pharmaceutical composition for administration of a double stranded ribonucleic acid (dsRNA) molecule to an animal, comprising the dsRNA molecule and a peptide, wherein the dsRNA molecule comprises about 10 to about 40 base pairs, wherein the peptide comprises about 5 to about 40 amino acids ... 02/16/06 - 20060035814 - Reagents and methods for smooth muscle therapies The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration. ... 12/29/05 - 20050288217 - Method for enhancing or inhibiting insulin-like growth factor-i The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same. ... 12/29/05 - 20050288216 - Novel transformed cell, method of screening antiaging agent and antiaging agents This invention provides a novel transformed cell useful in constructing an anti-aging agent screening system, a screening method which uses the same and an anti-aging agent, and it relates to a transformed cell in which a gene coding for (a) a protein capable of phosphorylating p38 protein, or (b) p38 ... 12/22/05 - 20050282740 - Methods and compositions for regulating protein-protein interactions The invention relates to methods and compositions of WW-domains as phosphoserine and phosphothreonine binding modules. The WW-domain containing polypeptides of the invention can be used, for example, to regulate cell growth; to treat neurodegenerative diseases; to screen for substances that modulated interactions between WW-domain containing polypeptides and phosphorylated ligands; as ... 12/08/05 - 20050272642 - Methods and compositions for protecting and treating at least one muscarinic receptor from dysfunction not resulting from oxidative stress, toxic actions of metals or infectious agents by administering a pyrophosphate analog Methods and compositions for protecting and treating a muscarinic receptor in a subject in need thereof from dysfunction not resulting from oxidative stress, toxic actions of metals or metal ions, or infectious agents by administering a pyrophosphate analog. ... 11/24/05 - 20050261170 - Folate conjugates and complexes Disclosed are conjugates and complexes that include a folate receptor ligand and one or more therapeutic molecules, such as onconase or a variant thereof such as rapLR1. The conjugates and complexes may be useful as primary therapeutic agents, which may be administered with additional therapeutic or diagnostic agents. Also disclosed ... 11/24/05 - 20050261169 - Peptide and peptide mimetic derivatives having integrin inhibitor properties iii and salts thereof as integrin inhibitors for the treatment of diseases, defects and inflammation caused by implants and of osteolytic diseases, such as osteoporosis, thrombosis, cardiac infarction and arteriosclerosis, and for the acceleration and strengthening of the integration process of the implant or of the biocompatible surface into the tissue. ... 11/17/05 - 20050256034 - Dioxolane analogs for improved inter-cellular delivery wherein R1 and R2 are defined herein, are useful in the treatment of cancer. For example, the compounds can be used to treat patients with cancer in which the cancer cells are deficient in nucleoside or nucleoside base transporters. ... 11/03/05 - 20050245435 - Compounds for enzyme inhibition Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. ... 11/03/05 - 20050245434 - Oxygenated dibenzo-alpha-pyrone chromoproteins A composition of oxygenated dibenzo-alpha-pyrone chromoproteins (DCP) and their isolation from shilajit, fossils of ammonites, corals and other invertebrates. More particularly, to the description of DCP-composition comprising oxygenated dibenzo-alpha-pyrone or its conjugates, phosphocreatine, proteins, fatty acyl esters of glycerol and other small ligands, e.g., carotenoids, sterols and aromatic acids, as ... 10/27/05 - 20050239687 - Methods and compositions for delivering sirna into mammalian cells Complex comprising a peptide carrier of SEQ ID NO:1 GALFLGFLGAAGSTMGAWSQPKR1KRKVR2 and an appropriate siRNA, wherein R1 represents any amino acid residue and more preferably K or S, R2 is null or represents one of the following groups: cysteamide, cysteine, thiol, amide, linear or ramified C1-C6 alkyl optionally substituted, primary or ... 10/13/05 - 20050227913 - Compositions and methods for less immunogenic protein formulations Methods and composition are described for low immunogenic protein, polypeptide or peptide formulations. The method comprises forming complexes of the protein, polypeptide or peptide with a binding agent which can be a serine containing compound or other phosphatidyl compounds or phospholipids. The complexes formed include simple complexes, micelles, cochleate structures, ... 10/06/05 - 20050222009 - Dual phase - pna conjugates for the delivery of pna through the blood brain barrier The invention provides molecule comprising a nucleic acid, a peptide ligand, which binds to a specific receptor and a positively charge peptide moiety with lysosomatic properties, useful in the delivery of a nucleic acid across a cellular membrane. The invention further relates to the use of these compounds for the ... 10/06/05 - 20050222008 - Conjugate for treating prokaryotic infections The invention relates to a conjugate for treating prokaryotic infections from a transport mediator penetrating the prokaryotic cell membrane and a desired compound to be introduced into the prokaryote and directed thereagainst, which compound is preferably a peptide nucleic acid (PNA) directed against a gene of the prokaryote giving antibiotic ... 08/25/05 - 20050187145 - Template-fixed peptidommetics as inhibitors of serine proteases Template-fixed β-hairpin peptidomimetics of the general formulae (1), wherein Z is a template-fixed chain of 7 to 11 α-amino acid residues which, depending on their positions in the chain (counted starting formteh N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining symbols in the ... 08/18/05 - 20050181984 - Cyclic peptide antifungal agents and process for preparation thereof R2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R═H) forms of the compounds. ... 08/11/05 - 20050176625 - Synthetic lipid mixtures for the preparation of a reconstituted surfactant The invention relates to reconstituted surfactants consisting of artificial phospholipids and peptides able to lower the air-liquid surface tension, more particularly to reconstituted surfactants, comprising special phospholipid mixtures and artificial peptides which are analogues of the natural surfactant SP-C protein for the treatment of respiratory distress syndrome (RDS) and other ... 07/28/05 - 20050164916 - Glycopeptide phosphonate derivatives Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents. ... 06/30/05 - 20050143290 - Substituted inositols and their use Inositol phosphate esters and conjugates formed between the compounds and a coupling partner are disclosed, in particular compounds based on a myo-inositol which is substituted at position 1 with a phosphate ester group, at position 2 with a sugar group and at position 4 and/or position 6 with an amino ... 06/09/05 - 20050124532 - Methods and compositions for treating hepatitis c virus A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided. ... 06/02/05 - 20050119163 - Sh2 domain binding inhibitors or a pharmaceutically acceptable salt or isomer thereof, wherein R1-R6 are as defined in the specification. These compounds are targeted for use as inhibitors of SH2 domain binding with a phosphoprotein, and are contemplated for use in a number of diseases including cancer. Also disclosed are pharmaceutical compositions comprising a ... ### FreshPatents.com Support |